LITAF
Basic information
Region (hg38): 16:11546875-11636381
Links
Phenotypes
GenCC
Source:
- Charcot-Marie-Tooth disease type 1C (Strong), mode of inheritance: AD
- Charcot-Marie-Tooth disease type 1C (Supportive), mode of inheritance: AD
- Charcot-Marie-Tooth disease (Moderate), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Charcot-Marie-Tooth disease, type 1C | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Neurologic | 11713717; 12525712; 19541485; 20301384; 23319192 |
ClinVar
This is a list of variants' phenotypes submitted to
- Charcot-Marie-Tooth disease type 1C (4 variants)
- Charcot-Marie-Tooth disease (3 variants)
- not provided (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the LITAF gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 34 | 37 | ||||
missense | 82 | 95 | ||||
nonsense | 1 | |||||
start loss | 2 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 2 | 2 | 4 | |||
non coding | 31 | 24 | 51 | 106 | ||
Total | 4 | 3 | 119 | 63 | 53 |
Variants in LITAF
This is a list of pathogenic ClinVar variants found in the LITAF region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-11547758-T-C | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) | ||
16-11547767-G-A | Charcot-Marie-Tooth disease, type I | Uncertain significance (Jun 14, 2016) | ||
16-11547784-T-C | Charcot-Marie-Tooth disease type 1C | Likely benign (Jan 12, 2018) | ||
16-11548005-G-C | Charcot-Marie-Tooth disease type 1C | Benign (Jan 13, 2018) | ||
16-11548010-C-T | Charcot-Marie-Tooth disease type 1C | Benign (Jan 13, 2018) | ||
16-11548080-G-T | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 12, 2018) | ||
16-11548144-A-C | Charcot-Marie-Tooth disease type 1C | Benign (Jan 12, 2018) | ||
16-11548201-A-C | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) | ||
16-11548215-T-C | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) | ||
16-11548222-G-T | Charcot-Marie-Tooth disease type 1C | Benign (Jan 12, 2018) | ||
16-11548238-G-T | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Mar 30, 2018) | ||
16-11548251-C-T | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Apr 27, 2017) | ||
16-11548273-T-G | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 12, 2018) | ||
16-11548386-T-C | Charcot-Marie-Tooth disease type 1C | Benign (Jan 12, 2018) | ||
16-11548420-T-G | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) | ||
16-11548467-T-C | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) | ||
16-11548583-T-G | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) | ||
16-11548688-T-C | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) | ||
16-11548704-G-A | Charcot-Marie-Tooth disease type 1C | Benign (Jan 13, 2018) | ||
16-11548733-C-T | Charcot-Marie-Tooth disease type 1C | Benign (Jan 13, 2018) | ||
16-11548755-C-T | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) | ||
16-11548820-T-TA | Charcot-Marie-Tooth disease, type I | Uncertain significance (Jun 14, 2016) | ||
16-11548821-A-T | Charcot-Marie-Tooth disease type 1C | Benign (Jan 12, 2018) | ||
16-11548841-A-G | Charcot-Marie-Tooth disease type 1C | Benign (Jan 13, 2018) | ||
16-11548914-T-C | Charcot-Marie-Tooth disease type 1C | Uncertain significance (Jan 13, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
LITAF | protein_coding | protein_coding | ENST00000571688 | 3 | 88385 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0308 | 0.823 | 125734 | 0 | 4 | 125738 | 0.0000159 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.224 | 97 | 103 | 0.938 | 0.00000635 | 1029 |
Missense in Polyphen | 21 | 31.116 | 0.67489 | 342 | ||
Synonymous | -0.175 | 48 | 46.5 | 1.03 | 0.00000333 | 342 |
Loss of Function | 1.13 | 3 | 5.99 | 0.501 | 2.54e-7 | 68 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000545 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000883 | 0.00000879 |
Middle Eastern | 0.0000545 | 0.0000544 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Plays a role in endosomal protein trafficking and in targeting proteins for lysosomal degradation (PubMed:23166352). Plays a role in targeting endocytosed EGFR and ERGG3 for lysosomal degradation, and thereby helps downregulate downstream signaling cascades (PubMed:23166352). Helps recruit the ESCRT complex components TSG101, HGS and STAM to cytoplasmic membranes (PubMed:23166352). Probably plays a role in regulating protein degradation via its interaction with NEDD4 (PubMed:15776429). May also contribute to the regulation of gene expression in the nucleus (PubMed:10200294, PubMed:15793005). Binds DNA (in vitro) and may play a synergistic role with STAT6 in the nucleus in regulating the expression of various cytokines (PubMed:15793005). May regulate the expression of numerous cytokines, such as TNF, CCL2, CCL5, CXCL1, IL1A and IL10 (PubMed:10200294, PubMed:15793005). {ECO:0000269|PubMed:15793005, ECO:0000269|PubMed:23166352, ECO:0000303|PubMed:15776429, ECO:0000305|PubMed:10200294}.;
- Disease
- DISEASE: Charcot-Marie-Tooth disease 1C (CMT1C) [MIM:601098]: A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot- Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. {ECO:0000269|PubMed:12525712, ECO:0000269|PubMed:15776429, ECO:0000269|PubMed:15786462, ECO:0000269|PubMed:16118794, ECO:0000269|PubMed:21896645, ECO:0000269|PubMed:23166352, ECO:0000269|PubMed:24604904}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in LITAF may be involved in extramammary Paget disease (EMPD) carcinogenesis. EMPD is a cancerous disease representing about 8% of all malignant skin cancers; it usually appears in the anogenital area and can be fatal by metastasizing to internal organs when left untreated for a long time. The clinical features are usually those of eczematous eruptions with weeping and crust formation. {ECO:0000269|PubMed:15197774}.;
- Pathway
- Lysosome - Homo sapiens (human)
(Consensus)
Recessive Scores
- pRec
- 0.207
Intolerance Scores
- loftool
- 0.0585
- rvis_EVS
- -0.05
- rvis_percentile_EVS
- 50.01
Haploinsufficiency Scores
- pHI
- 0.253
- hipred
- Y
- hipred_score
- 0.583
- ghis
- 0.508
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.212
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Litaf
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hematopoietic system phenotype;
Gene ontology
- Biological process
- regulation of cytokine production;regulation of transcription by RNA polymerase II;aging;positive regulation of I-kappaB kinase/NF-kappaB signaling;positive regulation of transcription by RNA polymerase II;cellular response to lipopolysaccharide;negative regulation of NIK/NF-kappaB signaling
- Cellular component
- Golgi membrane;nucleoplasm;lysosomal membrane;Golgi apparatus;cytosol;plasma membrane;cytoplasmic side of plasma membrane;intracellular membrane-bounded organelle;cytoplasmic side of early endosome membrane;cytoplasmic side of late endosome membrane;cytoplasmic side of lysosomal membrane
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription activator activity, RNA polymerase II-specific;protein binding;zinc ion binding;WW domain binding